摘要
目的:探讨黄芪和丹参提取物配伍对心肌梗死大鼠心肌组织病理变化的影响。方法:成功构建大鼠心梗模型后,随机分为模型组、黄芪组、丹参组、黄芪-丹参配伍组,每组8只大鼠,另设假手术组8只。术后48 h,黄芪、丹参及黄芪-丹参配伍组大鼠,均按20 mg·kg-1灌胃,其中黄芪-丹参配伍组,黄芪、丹参提取物按照1∶1配伍;对照组和假手术组给予生理盐水20 mL·kg-1灌胃。8周后测定大鼠的血流动力学变化;应用HE染色分析左心室心肌细胞组织形态学变化;采用Masson染色法检测左心室心肌胶原纤维;应用免疫组化法检测左心室心肌组织蛋白激酶D1(PKD1)的表达情况。结果:血流动力学检测结果表明,与模型组相比,假手术组、黄芪组-丹参组及黄芪丹参配伍组心脏左室收缩压(LVSP)、左室内压曲线最大上升和下降速率(±dp/dt)均显著升高(P<0.01),左室舒张末压(LVEDP)均显著降低(P<0.01),与丹参组相比,黄芪丹参配伍组LVSP,±dp/dt均明显升高(P<0.05)。HE染色分析,模型大鼠心肌细胞坏死严重,成纤维细胞增多,伴有炎症细胞浸润;黄芪、丹参单体组,细胞形态略显模糊,核肥大,成纤维细胞轻度增生,炎症细胞减少;黄芪-丹参配伍组细胞形态较清晰,成纤维细胞和炎症细胞少见。Masson染色结果表明,模型组大鼠心肌以胶原组织为主,各治疗组大鼠以红色心肌组织为主,间杂以胶原组织。免疫组化分析表明,模型组心肌组织胞浆中PKD1蛋白的表达极其明显(P<0.01);和模型组相比,黄芪-丹参组心肌组织胞浆中PKD1蛋白的表达明显下调(P<0.01),但仍清晰可见;和黄芪、丹参单体组相比,黄芪-丹参配伍组心肌组织胞浆中PKD1蛋白的表达进一步下调(P<0.05)。结论:黄芪-丹参配伍可明显改善心肌梗死后异常的血液流变学指标及组织的病理学病变,其作用机制可能与调控心肌组织PKD1蛋白的表达相关。
Objective：To study the effect of compatibility of Astragali Radix and Salviae Miltiorrhizae Radix et Rhizoma extract on pathological changes of myocardium in rats after myocardial infarction（MI）.Method：Left coronary artery of Sprague-Dawley rats were ligated to make MI models.The rats were randomly subjected to MI model group,astragalus group,Salviae Miltiorrhizae Radix et Rhizoma group,compatibility of Astragali Radix and Salviae Miltiorrhizae Radix et Rhizoma and sham-operated group,each group consisted of 8 rats.All the treatment groups were orally given 20 mg·kg-1·d-1 drug extract,and the MI group and sham-operated group were fed 0.9% sodium chloride 20 mL·kg-1·d-1.8 weeks later,the rats were sacrificed,the hemodynamic changes in rats were determined,and the segmental heart samples were collected for hematoxylin and eosin staining,masson staining and histological evaluation on expression of protein kinase D1（PKD1）.Result：Compared with the MI group,the left ventricular systolic pressure（LVSP） and maximal decrease and increase rate of pressure in left ventricle of Astragali Radix group,Salviae Miltiorrhizae Radix et Rhizoma group,compatibility of Astragali Radix and Salviae Miltiorrhizae Radix et Rhizoma or sham-operated group increased significantly（P0.01）,while the left ventricular end diastolic pressure（LVEDP） decreased significantly（P0.01）.There were serious myocardial necrosis,increased fibroblasts,accompanied by inflammatory cell infiltration in the rat of MI group,and slightly fuzzy cell morphology,nuclear hypertrophy,mild proliferation of fibroblasts,inflammatory cells decreasing in the Astragali Radix or Salviae Miltiorrhizae Radix et Rhizoma group,while clearer cell morphology,rare fibroblasts and inflammatory cells in the compatibility of Astragali Radix and Salviae Miltiorrhizae Radix et Rhizoma group,according to the HE staining analysis.The masson staining results showed that the MI group consisted of more myocardial collagen tissue,yet each treatment group consist of mainly red myocardial tissue,intermingled collagen tissue.The PKD1 protein expression in the cytoplasm of myocardial tissue of the MI group increased significantly（P0.01）,compared to all the treatment group,despite of decreasing obviously,but still visible in the Astragali Radix or Salviae Miltiorrhizae Radix et Rhizoma group.And the PKD1 protein expression in the compatibility of Astragali Radix and Salviae Miltiorrhizae Radix et Rhizoma group declined significantly compared to the Astragali Radix or Salviae Miltiorrhizae Radix et Rhizoma group（P0.05）.Conclusion：Our study reveals that the compatibility of Astragali Radix and Salviae Miltiorrhizae Radix et Rhizoma can significantly ameliorate the abnormal hemorheological indicators and pathologic lesions after myocardial infarction,which may be related to the expression regulation of PKD1 protein in myocardial tissue.
出处
《中国实验方剂学杂志》
CAS
北大核心
2013年第8期175-179,共5页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家自然科学基金面上项目(81173372)
国家自然科学基金青年基金项目(81202791)
关键词
黄芪
丹参
配伍
心肌梗死
蛋白激酶D
Astragali Radix
Salviae Miltiorrhizae Radix et Rhizoma
compatibility
myocardial infarction
protein kinase D
作者简介
杨雷，医学博士，讲师，从事中药抗心血管疾病发病机制研究，Tel：0377-62071309，E-mail：yanglei200609@126．com
[通讯作者]毛秉豫，医学博士，教授，从事心血管疾病的气血并治方药研究，Tel：0377-62232916，E-mail：maobingyu2005@126．com.
